Overview

Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer

Status:
RECRUITING

Trial end date:
2029-12-31

Target enrollment:

Participant gender:

Summary

This phase II trial tests how well immunotherapy (toripalimab) works for reducing the risk of cancer recurrence after surgery in patients with mismatch repair deficient stage IIB, IIC, or III colon cancer.

Phase:

PHASE2

Details

Lead Sponsor:

Emory University

Collaborators:

Coherus Oncology, Inc.
National Cancer Institute (NCI)

Treatments:

Biopsy
Colonoscopy
Specimen Handling
toripalimab